Edwards Lifesciences Corp (NASDAQ:EW) saw a notable insider transaction involving Corporate Vice President Donald E. Bobo Jr., Strategy/Corp Development. On May 27, 2026, Mr. Bobo Jr. executed sales of the company’s common stock, divesting 23,145 shares.
These transactions accounted for a total value estimated at $2,000,193. The selling prices were observed to range between $86.27 and $86.57 per share, resulting in a weighted average sale price of $86.4201 across multiple trades.
The timing of these sales is noteworthy as the stock was trading near its 52-week high of $88.28, with shares priced at $86.53 at the time of the report. Following this specific transaction, Mr. Bobo Jr.'s holdings were structured across various accounts. He currently holds an indirect stake of 98,611 common shares through a trust, alongside a direct ownership of 22,798.2532 shares and another indirect holding totaling 30,969.5756 shares via a 401(k) plan.
The recent insider activity is set against a backdrop of significant positive corporate developments for Edwards Lifesciences. The company released strong financial results for the first quarter of 2026. During this period, revenue reached $1.65 billion, marking a substantial year-over-year increase of 12.7% when measured on a constant currency basis.
Furthermore, Edwards Lifesciences' earnings per share increased by 22% compared to the previous year, reaching $0.78. This figure not only exceeded both general market expectations (Street estimates) but also surpassed the company's own internal guidance.
The robust quarterly performance prompted several major financial institutions to adjust their outlook and price targets for EW. TD Cowen reinforced its positive stance, maintaining a Buy rating and setting a $97.00 price target. Similarly, Bernstein SocGen Group updated its price target to $96, attributing the adjustment to the company's strong quarterly performance and better-than-expected results across all operational business segments.
Stifel maintained a Buy rating while raising its price target to $110.00. This firm specifically highlighted the continued double-digit growth trajectory of the transcatheter aortic valve replacement product line. Barclays also increased its price target to $110, alongside maintaining an Overweight rating and boosting its next-twelve-month EBITDA estimate to $2.44 billion.
In addition to financial performance, Edwards Lifesciences announced a key executive transition: the appointment of Theodora Mistras as the new chief financial officer. This role is effective at the end of May, succeeding Scott Ullem. These cumulative developments signal a period characterized by both significant operational success and positive market reassessment for the medical device firm.
Key Takeaways and Market Implications
- Insider selling by a Corporate Vice President (Donald E. Bobo Jr.) occurred when the stock was near its 52-week high, which some may interpret as a lack of confidence.
- The current P/E ratio for Edwards Lifesciences is 46.84, indicating a high valuation relative to current earnings, which could present a risk if growth slows.
- While the transcatheter aortic valve replacement product shows double-digit growth, reliance on specific products or segments represents an operational concentration risk.